Preterm birth risk can be assessed by symptoms of labour such as contractions, and vaginal bleeding. However these biophysical markers are not as accurate in predicting preterm birth as fetal fibronectin, a biochemical marker that can often be detected before the biophysical markers.1
The use of fetal fibronectin (fFN) testing can help to reduce unnecessary admissions, shorten hospitalisations and help you direct care and resources to the patients who need it most.
Preterm labour can be associated with substantial anxiety for patients. Hospitals can use fFN testing to help themselves and their patients to truly distinguish between those who are at risk of preterm labour from those who are at very low risk. This allows you to achieve:
This link will take you to the information intended for healthcare professionals outside of the United States. Because these pages concern the international distribution activities of the QuikCheckTM fFN Test, which are not necessarily governed by US law, contents of the international pages may contain information that does not pertain to US users, including certain products that may not be cleared or approved by US Food & Drug Administration for promotion or sale in the United States. Click “Continue” to proceed, or click “Cancel” to remain in the US site.
Caution: The QuikCheck fFNTest is not sold or offered for sale in the United States or Canada.
Hologic, Inc. does not review nor control the content on non-Hologic websites. This link does not constitute an endorsement by Hologic of the content of the site you are about to visit. Hologic privacy procedures do not apply to the owners of a non-Hologic website.